A 36-week, randomized, double-blind, placebo controlled, parallel
group trial to assess the efficacy and safety of PXL065 versus
placebo in noncirrhotic, biopsy-proven Nonalcoholic Steatohepatitis
(NASH) patients
Please contact us for more information or to learn if you are eligible to participate.
